期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
Clinical Research Progress of Crohn
1
作者 pingping mei Wenzhe Feng +2 位作者 Peng Shi Yu Zhuang Wenxiu Zhang 《Journal of Biosciences and Medicines》 CAS 2022年第8期35-46,共12页
Crohn’s Disease (CD) is a chronic recurrent inflammatory bowel disease with unknown etiology, most common in the terminal ileum and adjacent colon. In the past 30 years, the global prevalence of CD has continued to r... Crohn’s Disease (CD) is a chronic recurrent inflammatory bowel disease with unknown etiology, most common in the terminal ileum and adjacent colon. In the past 30 years, the global prevalence of CD has continued to rise. Although the etiology is unknown, studies have shown that it is closely related to geographical environment, microfold cell damage, intestinal flora changes, epithelial barrier damage, immune dysfunction and low. The main clinical manifestations of CD are abdominal pain, chronic diarrhea, fatigue, fever and weight loss. At present, 5-aminosalicylic acid, antibiotics, glucocorticoids, immunosuppressants and biological agents are mainly used for treatment, but the drug effect is limited and the effect is not good. Recent studies have shown that Mesenchymal Stem Cells (MSC) can down-regulate immune response and promote tissue healing, which has certain safety and effectiveness in the treatment of moderate and severe CD, and has broad application prospects, but also has certain limitations. This paper summarizes the application and efficacy of related therapies in CD, providing a reference for clinicians. 展开更多
关键词 CROHN Crohn’s Drug Treatment Mesenchymal Stem Cells
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部